45 filings
8-K
XYNPW
Xynomic Pharmaceuticals Holdings, Inc.
29 Jun 20
Departure of Directors or Certain Officers
2:43pm
8-K
XYNPW
Xynomic Pharmaceuticals Holdings, Inc.
14 May 20
Other Events
3:36pm
8-K
XYNPW
Xynomic Pharmaceuticals Holdings, Inc.
30 Mar 20
Other Events
11:01am
8-K
XYNPW
Xynomic Pharmaceuticals Holdings, Inc.
27 Mar 20
Other Events
2:57pm
8-K
XYNPW
Xynomic Pharmaceuticals Holdings, Inc.
27 Sep 19
Regulation FD Disclosure
4:31pm
8-K
ddx5wd
23 Sep 19
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
6:01am
8-K
u38ry3
20 Sep 19
Departure of Directors or Certain Officers
2:41pm
8-K
sp2af3ipk gqtar8
13 Sep 19
Regulation FD Disclosure
3:59pm
8-K
ikey1qak
6 Sep 19
Entry into a Material Definitive Agreement
11:47am
8-K
npwhgi6s6356wq vdv
30 Aug 19
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
8:42am
8-K
i4rr7omwg 9t6185
27 Aug 19
Submission of Matters to a Vote of Security Holders
6:02am
8-K
c6g0v6r0d
16 Aug 19
Regulation FD Disclosure
4:44pm
8-K
yoob5xtwe
7 Aug 19
Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
4:07pm
8-K
kex3k84prs9kq1
1 Aug 19
Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA
7:01am
8-K
p5k 6rrhdurrb2hs9ed5
30 Jul 19
Xynomic Received China Approval to Start 2 Pivotal Lymphoma Clinical Trials
8:09am
8-K
0b1hdc 2h79
17 Jul 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
3li9m
11 Jul 19
Entry into a Material Definitive Agreement
6:30am
8-K/A
8geg6nbcejf3aui98i
5 Jul 19
Entry into a Material Definitive Agreement
11:47am
8-K
mvut6x
21 Jun 19
Regulation FD Disclosure
6:02am
8-K
ojw3s
12 Jun 19
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
10:20am